Adalimumab for the treatment of psoriatic arthritis

Expert Review of Clinical Immunology

Volumn 5, Issue 6, 2009, Pages 671-681

  Poddubnyy, Denis A ^a   Rudwaleit, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adalimumab; Monoclonal antibody; Psoriatic arthritis; Spondyloarthritis; TNF

Indexed keywords

ADALIMUMAB; ALEFACEPT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; USTEKINUMAB;

ABNORMAL LABORATORY RESULT; ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROHN DISEASE; DEMYELINATING DISEASE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEART FAILURE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LUPUS LIKE SYNDROME; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NEUROENDOCRINE TUMOR; OPPORTUNISTIC INFECTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SINUSITIS; SKIN CANCER; TUBERCULOUS PERITONITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 77949858776     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.50     Document Type: Review

References (26)

1. Leonard DG, ODuffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin. Proc. 53(8), 511-518 (1978).
2. Shbeeb M, Uramoto KM, Gibson LE, OFallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J. Rheumatol. 27(5), 1247-1250 (2000).
3. Gelfand JM, Gladman DD, Mease PJ et al. Epidemiology of psoriatic arthritis in the population of the United States. J. Am. Acad. Dermatol. 53(4), 573 (2005).
4. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 61(2), 233-239 (2009).
5. Ritchlin CT, Kavanaugh A, Gladman DD et al. Treatment recommendations for psoriatic arthritis. Ann. Rheum. Dis. 68(9), 1387-1394 (2009).
6. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52(4), 1227-1236 (2005).
7. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 64(8), 1150-1157 (2005).
8. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 50(7), 2264-2272 (2004).
9. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52(10), 3279-3289 (2005).
10. Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor a antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 60(4), 976-986 (2009).
11. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 54(5), 1638-1645 (2006).
12. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373(9664), 633-640 (2009).
13. Papp KA, Caro I, Leung HM, Garovoy M, Mease PJ. Efalizumab for the treatment of psoriatic arthritis. J. Cutan. Med. Surg. 11(2), 57-66 (2007).
14. Sieper J, Rudwaleit M, Braun J. Adalimumab for the treatment of ankylosing spondylitis. Expert Opin. Pharmacother. 8(6), 831-838 (2007).
15. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117(2), 244-279 (2008).
16. Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann. Rheum. Dis. 66(2), 163-168 (2007).
17. Genovese MC, Mease PJ, Thomson GT et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J. Rheumatol. 34(5), 1040-1050 (2007).
18. Gladman DD, Mease PJ, Ritchlin CT et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 56(2), 476-488 (2007).
19. Mease PJ, Ory P, Sharp JT et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann. Rheum. Dis. 68(5), 702-709 (2009).
20. van den Bosch F, Manger B, Goupille P et al. Adalimumab (Humira® ) is effective in treating patients with psoriatic arthritis (PsA) in real life clinical practice: results of the STEREO trial. Ann. Rheum. Dis. 66(Suppl. II), 98 (2008).
21. Anandarajah AP, Ory P, Salonen D, Feng C, Wong RL, Ritchlin CT. Effect of adalimumab on joint disease features of patients with psoriatic arthritis detected by Magnetic Resonance Imaging. Ann. Rheum. Dis. (2009) (Epub ahead of print).
22. van Kuijk AW, Gerlag DM, Vos K et al. A prospective, randomized, placebocontrolled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann. Rheum. Dis. 68(8), 1303-1309 (2009).
23. Heiberg MS, Koldingsnes W, Mikkelsen K et al. The comparative one-year performance of anti-tumor necrosis factor a drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 59(2), 234-240 (2008).
24. Burmester GR, Mease PJ, Dijkmans BA et al. Adalimumab safety and mortality rates from global clinical trials of six immunemediated inflammatory diseases. Ann. Rheum. Dis. (2009) (Epub ahead of print).
25. Rudwaleit M, Claudepierre P, Wordsworth P et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J. Rheumatol. 36(4), 801-808 (2009).
26. Papoutsaki M, Costanzo A, Chimenti MS et al. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. Expert Opin. Biol. Ther. 8(3), 363-370 (2008).